This handout is for atrial flutter in the long-term endurance athlete. Your care team identified this based on: new palpitations, exertional intolerance, or unexpected drop in training power output in long-term endurance athlete (≥10 yr cumulative high-volume training) — afl/af likely.
Other reasons your team may use this plan: 12-lead ecg with atrial flutter pattern + echo showing la dilation + lv mass increase + low resting hr (athlete's-heart substrate); marathon / cycling / triathlon / cross-country skiing background ≥10 y + new-onset afl/af; often presents during taper or after very long event; syncope or near-syncope during endurance session — afl with rapid av conduction, or rate-related ischemia in young athlete; full arrhythmia + ischemic workup mandatory.
Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.
| Medication | Starting dose | How | When | What it does |
|---|---|---|---|---|
| esmolol | 500 mcg/kg IV bolus (or skip in stable patient) then 25-100 mcg/kg/min infusion titrate to HR 80-110 | IV | continuous infusion | PREFERRED acute IV BB in athlete cohort — ultra-short half-life (~9 min) allows fine titration if hemodynamics shift; respects baseline bradycardia; ACC/AHA 2024 Class I rate control |
| metoprolol_tartrate | 12.5-25 mg PO BID low-dose initial; titrate cautiously to HR 80-110 in NSR <90 | PO | BID | Low-dose b1-selective preserves exercise capacity better than non-selective; cautious because baseline resting HR 40-55 in athletes; ACC/AHA 2024 Class I |
| diltiazem | 0.25 mg/kg IV bolus (max 20 mg) then 5-15 mg/h infusion; PO 120-360 mg daily extended release | IV/PO | continuous or daily ER | Alternative when BB poorly tolerated due to athlete's baseline bradycardia or reactive airways; ACC/AHA 2024 Class I rate control; avoid in EF <40 |
| apixaban | 5 mg PO BID (2.5 mg BID if 2 of: age ≥80, wt ≤60 kg, Cr ≥1.5) | PO | BID | PREFERRED AC — DOAC trumps warfarin in active-lifestyle athlete (no INR monitoring, no diet interference, slightly lower bleed); ARISTOTLE foundational (PMID 21870978); ACC/AHA 2024 (PMID 38753446) Class I |
| rivaroxaban | 20 mg PO with food (15 mg if CrCl 15-50) | PO | once daily | Once-daily alternative DOAC; ROCKET-AF; ACC/AHA 2024 |
| warfarin | 5 mg daily; INR target 2-3 | PO | daily | Reserve for mechanical valve / severe CKD / cost; INR + diet management onerous for endurance athletes |
| amiodarone | 150 mg IV bolus then 1 mg/min × 6 h then 0.5 mg/min × 18 h; oral 200-400 mg daily load then 100-200 mg maintenance | IV/PO | continuous + daily | AVOID first-line in young endurance athlete — long-term pulmonary, thyroid, hepatic, ocular toxicity prohibitive over expected decades of life; reserve for bridge to ablation or LV dysfunction; ACC/AHA 2024 IIb |
| CTI ablation for typical AFL | Single-session catheter ablation of cavotricuspid isthmus | procedural | one-time | HRS/EHRA/ECAS 2017 (Calkins PMID 28506916) — >95% acute success for typical AFL; preferred earlier in young athlete to avoid decades of drug therapy + facilitate return to training |
| synchronized DCCV 50-100 J biphasic | 50-100 J synchronized biphasic, escalate to 200 J | procedural | as needed | Low DCCV threshold in athlete cohort given desire to restore symptom-free training; 4-wk AC pre-CV if onset >48h or unclear; ACC/AHA 2024 Class I |
| training volume reduction to <5 h/wk submaximal × 3-6 mo trial | Reduce weekly endurance hours to <5 h/wk + avoid prolonged events for 3-6 mo as substrate-reversal trial | lifestyle | sustained | Andersen 2013 marathon cohort (PMID 23736857) + Mont 2002 (PMID 12099811) + Mohanty 2016 (PMID 27340861) — dose-response with reversibility; single most powerful long-term intervention in this cohort |
| CPAP for OSA if positive | Per sleep study titration | lifestyle/device | nightly | CAPPS-style cohorts show 30-50% AFL/AF recurrence reduction with effective OSA treatment; common comorbidity in middle-aged endurance males |
| alcohol cessation | Zero alcohol × 6 mo trial; reassess | lifestyle | sustained | Alcohol-Abstinence trial (Voskoboinik NEJM 2020 PMID 31893513) — abstinence reduces AF recurrence; endurance cohort frequently moderate-heavy drinkers |
Plan: Endurance-athlete AFL — cautious low-dose BB (or diltiazem) given baseline bradycardia + low DCCV threshold + early CTI ablation + training-volume reduction anchor + OSA/alcohol screen — ACC/AHA 2024 (PMID 38753446) + ESC 2020 Sports Cardiology (PMID 32860412)
Contact your care team if any of the following happen:
Call 911 or go to the nearest emergency room right away if you have:
EP referral for early CTI ablation candidacy (typical AFL >95% acute success); cardiology q3 mo first year then q6-12 mo; sleep medicine if OSA positive; sport-medicine + cardiac rehab gradual return-to-training plan; AC reassessment annually per CHA2DS2-VASc; cardiac MRI surveillance if pathologic dilation suspected; consider LAAO if ablation refractory + AC contraindicated
Guideline: 2024 ACC/AHA/ACCP/HRS AF + AFL Joint Guideline (Joglar PMID 38753446) + ESC 2024 AF (Van Gelder PMID 39050851) + ESC 2020 Sports Cardiology (Pelliccia PMID 32860412) + HRS/EHRA/ECAS 2017 Ablation Consensus (Calkins PMID 28506916)